| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514424000 | Chalcogen bonded directly to the five-membered hetero ring by nonionic bonding | 74 |
| 20100048665 | 3-AMINOPYRROLIDONE DERIVATIVES - 3-aminopyrrolidone compounds and pharmaceutically acceptable salts thereof that are active as sodium and/or calcium channel modulators and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases. | 02-25-2010 |
| 20090270478 | ION CHANNEL MODULATING ACTIVITY II - Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g., atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes. | 10-29-2009 |
| 20130065936 | MODULATION OF BIOACTIVE EPOXY-FATTY ACID LEVELS BY PHOSPHODIESTERASE INHIBITORS - The present invention provides method for increasing levels of epoxygenated fatty acids by administration of a phosphodiesterase inhibitor. | 03-14-2013 |
| 20090048329 | Substituted Pyrrolidine Compounds With Central Nervous System Activity - Provided herein are substituted pyrrolidines that demonstrate binding at biogenic amine transporters and can be synthesized by a methodology based on a chiral dirhodium catalyst. Compositions comprising substituted pyrrolidines can be used to treat central nervous system disorders such as schizophrenia. | 02-19-2009 |
| 20120238614 | ANTICONVULSANT COMBINATION THERAPY - The present invention is directed to a pharmaceutical composition comprising a Compound (a) of a class of peptide Compounds and at least one further Compound (b) for the prevention, alleviation or/and treatment of epileptic seizures. | 09-20-2012 |
| 20090131508 | Use of 2-Oxo-1-Pyrrolidone Derivatives for the Preparation of a Drug - The present invention relates to the use of brivaracetam for the preparation of drugs effective for the prevention or treatment of progressive myoclonic epilepsies. | 05-21-2009 |
| 20110281929 | Pharmaceutical Compositions Comprising 2-Oxo-1-Pyrrolidine Derivatives - The present invention relates to an immediate release formulation of pharmaceutical compounds. | 11-17-2011 |
| 20100056604 | METHODS FOR STIMULATING NERVOUS SYSTEM REGENERATION AND REPAIR BY INHIBITING PHOSPHODIESTERASE TYPE IV - The invention relates to the novel identification of inhibitors of phosphodiesterase type 4 (“PDE4”) as agents which can reverse inhibition of neural regeneration in the mammalian central and peripheral nervous system. The invention provides compositions and methods using agents that can reverse the inhibitory effects on neural regeneration by regulating PDE4 expression. A composition comprising at least one PDE4 inhibitor in an amount effective to inhibit PDE4 activity in a neuron when administered to an animal is provided. Methods for regulating (e.g., promoting) neural growth or regeneration in the nervous system, methods for treating injuries or damage to nervous tissue or neurons, and methods for treating neural degeneration associated with disorders or diseases, comprising the step of administering to an animal a composition comprising a therapeutically effective amount of an agent which inhibits phosphodiesterase IV activity in a neuron are provided. | 03-04-2010 |
| 20110201665 | Compositions, Methods, and Kits for Treating Influenza Viral Infections - The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infection caused by an influenza virus). | 08-18-2011 |
| 20090088464 | Merged ion channel modulating compounds and Uses Thereof - Merged compounds of ion channel modulating compounds, including, for example, merged compounds of the ion channel modulating compound of the following formula: (I) are described herein, as well as methods of making and using such merged compounds and pharmaceutical compositions containing such merged compounds. | 04-02-2009 |
| 20090036514 | Therapeutic effects of Bryostatins, Bryologs, and other related substances on Ischemia/stroke-induced memory impairment and brain injury - The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or other neurotrophic factors to treat stroke. Specifically, the present invention provides methods of treating stroke comprising the steps of identifying a subject having suffered a stroke and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of stroke. | 02-05-2009 |
| 20100087506 | CYCLIC AMINE COMPOUND - Provision of a compound having a superior androgen receptor regulating action. | 04-08-2010 |
| 20090291999 | Agent Exhibiting a Neurotropic, Neuromodulator, Cerebrovascular and Anti-Stroke Activity - The invention relates to medicine, in particular to pharmacology and to medicinal agents exhibiting a neurotropic and cerebrovascular activity. The novelty of the invention consists in that an N-carbomoyl-methyl-4-phenyl-2-pyrrolidon agent injected into an organism displays an universal pronounced effect in the form of the one hundred percent survival of animals, eliminates the development of a neurological symptom complex of a cerebral stroke of different aetiologies, localizes a cerebral affection area and the destructive development thereof. It is proved, that the inventive agent exhibits universal neurotropic (neuromodulator) activity and produces a neuroprotective-cerebrovascular action. | 11-26-2009 |
| 20090298908 | DMAE AS SOLE AGENT FOR THE TREATMENT OF MILD COGNITIVE IMPAIRMENT - The present invention relates to the use, as sole active ingredient, of dimethylaminoethanol (DMAE) in free form or in the form of salts or of esters and also of hydrates and solvates thereof, for the manufacture of a medicament for use in the treatment of a non-dementia mild cognitive impairment characterized by an amnestic syndrome of hippocampal type. | 12-03-2009 |
| 20080312309 | CONTROLLED RELEASE ORAL FORMULATIONS OF ION CHANNEL MODULATING COMPOUNDS AND RELATED METHODS FOR PREVENTING ARRHYTHMIA - The present invention provides methods of treating and preventing arrhythmia and other diseases or disorders, using ion channel modulating compounds, including vernakalant hydrochloride. The present invention further provides controlled release oral formulations and dosages of vernakalant hydrochloride, which are effective in preventing arrhythmia. Certain methods and formulations of the present invention are adapted for the treatment and prevention of arrhythmia and other disease or disorders in subjects identified as having altered drug metabolism due to polymorphism of the gene encoding cytochrome P450 2D6. | 12-18-2008 |
| 20080269316 | Pharmaceutical Compositions Comprising Levetiracetam and Process for Their Preparation - The present invention relates to a pharmaceutical composition comprising levetiracetam as active ingredient and 2.0 to 9.0% per weight of disintegrant, 0.0 to 3.0% per weight of gliding agent, 0.5 to 6.0% per weight of binder, and 0.0 to 1.0% per weight of lubricant, with respect to the total weight of the pharmaceutical composition, and to a process for its preparation. | 10-30-2008 |
| 20090036515 | METHOD FOR TREATING COLONIC VISCEROSENSITIVITY AND SPASTICITY - There is provided a method of treating colonic viscerosensitivity and spasticity induced by a colonic examination chosen from colonic endoscopy and of barium/air contrast colonic radiography and virtual colonoscopy. The method comprises prescribing and/or administering to a patient in need thereof a pharmaceutically effective oral, sub-lingual, nasal or transdermic dose of a non-centrally-acting opioid agonist for a period of at least two days before the colonic examination. | 02-05-2009 |
| 20110207794 | PHARMACEUTICAL COMPOSITION - The present invention relates to an oral controlled release pharmaceutical composition in the form of a unit dosage form comprising:
| 08-25-2011 |
| 20090082422 | DEUTERIUM-ENRICHED LEVETIRACETAM - The present application describes deuterium-enriched levetiracetam, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-26-2009 |
| 20100152276 | DEUTERATED AMINOCYCLOHEXYL ETHER COMPOUNDS AND PROCESSES FOR PREPARING SAME - This invention is directed to deuterated aminocyclohexyl ether compounds and processes for preparing same and methods of using same. | 06-17-2010 |
| 20100240728 | Co-Crystals of Pyrrolidinones - The present invention relates to new co-crystals of pyrrolidinones having the formula (I) wherein R | 09-23-2010 |
| 20100210706 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS - The present invention relates to a compound represented by the following formula: | 08-19-2010 |
| 20120245215 | Co-Crystals of Pyrrolidinones - The present invention relates to new co-crystals of pyrrolidinones having the formula (I) wherein R | 09-27-2012 |
| 20090062372 | Glycopyrronium Salts and Their Therapeutic Use - A glycopyrronium salt such as glycopyrronium iodide has a lower glass transition temperature than glycopyrronium bromide. It is therefore more suitable for formulation. | 03-05-2009 |
| 20090069404 | DEUTERIUM-ENRICHED VERNAKALANT - The present application describes deuterium-enriched vemakalant, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-12-2009 |
| 20110118329 | USES OF ION CHANNEL MODULATING COMPOUNDS - Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. | 05-19-2011 |
| 20110178152 | COMPOSITION COMPRISING S-ALLYLMERCAPTO-N-ACETYLCYSTEINE (ASSNAC) FOR UP-REGULATION OF CELLULAR GLUTATHIONE LEVEL - The present invention relates to S-allylmercapto-N-acetylcysteine (ASSNAC) and its pharmaceutically acceptable salts and solvates, which are useful for up-regulation of cellular glutathione levels and expression of phase II detoxifying enzymes. The invention further provides methods of use thereof in the prevention, alleviation or treatment of oxidative stress induced by reactive oxygen species (ROS). | 07-21-2011 |
| 20100056603 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF - Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local anesthesia. | 03-04-2010 |
| 20090215857 | Therapeutic Pyrrolidines - The present invention provides for compounds of Formula (I), | 08-27-2009 |
| 20120035239 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES - The invention concerns 2-oxo-1-pyrrolidine derivatives of formula I, | 02-09-2012 |
| 20110257241 | 3-PHENYL-3-METHOXYPYRROLIDINE DERIVATIVES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION - The present invention relates to novel 3-phenyl-3-methoxy-pyrrolidine derivatives, useful for modulating extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders. In other aspects the invention relates to pharmaceutical compositions comprising the 3-phenyl-3-methoxy-pyrrolidine derivatives of the invention and to the use of these compounds for therapeutic applications. | 10-20-2011 |
| 20100029744 | Methods for Alzheimer's Disease Treatment and Cognitive Enhancement - The present invention relates to compositions comprising a combination of PKC activators and PKC inhibitors and methods to modulate α-secretase activity; improve or enhance cognitive ability; and/or reduce neurodegeneration in individuals suffering from diseases that impair cognitive ability, particularly Alzheimer's Disease. The invention also relates to methods for improving or enhancing cognitive ability. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP (sAPP) comprising the activation of protein kinase C (PKC) in the brain and inhibiting PKC in peripheral tissues. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are preferred PKC activators and Vitamin E is a preferred PKC inhibitor for use in the inventive composition. | 02-04-2010 |
| 20080287522 | BENZYLATED PDE4 INHIBITORS - The present invention is directed to a method for reducing the emetogenic effects of PDE inhibitors, and more particularly is directed to compounds having PDE4 inhibition activity with little or no emetogenic side-effects, and chemical methods including benzylation for preparing such compounds. A benzyl group may be attached to either a carbon or nitrogen atom of a PDE4 inhibitor. Suitable benzylation chemistry is to extract a hydrogen from a PDE4 inhibitor, preferably with a base, and then react the resulting nucleophilic PDE4 inhibitor with a benzylating agent, e.g., benzyl bromide or a derivative thereof. | 11-20-2008 |
| 20110306650 | PROCESS FOR THE PREPARATION OF GLYCOPYRRONIUM CHLORIDE - The invention concerns a method for preparing glycopyrronium chloride, and its use in pharmaceutical applications. | 12-15-2011 |
| 20110306649 | PRODRUGS OF ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF - Prodrugs of ion channeling modulating compounds, including, for example, prodrugs of the ion channel modulating compound of the following formula: | 12-15-2011 |
| 20120046336 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION - This invention relates to treating age-related cognitive impairment. This invention in particular relates to the use of inhibitors of synaptic vesicle protein 2A (SV2A), such as levetiracetam, seletracetam, and brivaracetam, in improving cognitive function in subjects that exhibit age-related cognitive impairment or are at risk thereof, including, without limitation, subjects having or at risk for Mild Cognitive Impairment (MCI), Age-related Cognitive Decline (ARCD) or Age-Associated Memory Impairment (AAMI). | 02-23-2012 |
| 20100120890 | ION CHANNEL MODULATING ACTIVITY I - Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, early afterdepolarizations and prolongation of QT interval may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes. | 05-13-2010 |
| 20120022127 | PROCESS FOR PREPARING PYRROLIDINIUM SALTS - A two step process for preparing a compound of formula I | 01-26-2012 |
| 20120214859 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION - This invention relates to methods and compositions for treating central nervous system (CNS) disorders with cognitive impairment. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating central nervous system (CNS) disorders with cognitive impairment in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, amyotrophic lateral sclerosis and cancer-therapy-related cognitive impairment. | 08-23-2012 |
| 20100292296 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS - Novel ligand compounds having the general formula (I): | 11-18-2010 |
| 20120258996 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS - Novel ligand compounds having the general formula (I): | 10-11-2012 |
| 20120095073 | ION CHANNEL MODULATING ACTIVITY II - Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g. atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes. | 04-19-2012 |
| 20110275693 | Pharmaceutical Compositions Comprising 2-Oxo-1-Pyrrolidine Derivatives - The present invention relates to an immediate release formulation of pharmaceutical compounds. | 11-10-2011 |
| 20120101145 | Oligomer-Containing Pyrrolidine Compounds - The invention relates to (among other things) oligomer-containing pyrrolidine compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer. | 04-26-2012 |
| 20080255222 | PHARMACEUTICALLY ACTIVE BENZSULFONAMIDE DERIVATIVES AS INHIBITORS OF PROTEIN JUNKINASES - The present invention relates to benzsulfonamide derivatives of formula I and methods of use thereof. The benzsulfonamide derivatives of the present invention are efficient modulators of the JNK pathway. In particular the benzsulfonamide derivatives of the present invention are selective inhibitors of JNK 2 and 3. | 10-16-2008 |
| 20080242720 | KAPPA-OPIATE AGONISTS FOR THE TREATMENT OF DIARRHEA-PREDOMINANT AND ALTERNATING IRRITABLE BOWEL SYNDROME - The present invention concerns methods useful in treating one or more subtypes of irritable bowel syndrome (IBS), or useful in treating diarrhea. The invention relates to the use of peripherally selective kappa-opiate agonists, especially N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide and/or a pharmaceutically acceptable salt thereof for treating a subject having diarrhea-predominant IBS (IBS-D) or IBS with alternating diarrhea and constipation (IBS-A), or a subject having diarrhea. | 10-02-2008 |
| 20080227849 | Orally Disintegrable Solid Preparation Comprising Povidone-Iodine - An orally disintegratable solid preparation comprising povidone-iodine as an active ingredient, which is obtained by direct powder compression of a mixture containing a granular sugar alcohol and povidone-iodine, wherein the mixture does not contain a basic ingredient and is not subjected to wet granulation. High quality solid preparation as an orally disintegratable preparation comprising povidone-iodine, which have a constant content of povidone-iodine per a single unit solid preparation and maintain stability of iodine, are provided. | 09-18-2008 |
| 20080227848 | Assays - A method of identifying an agent which modulates 2-oxoglutarate dependent oxygenase activity, the method comprising contacting a 2-oxoglutarate dependent oxygenase and a test agent in the presence of a substrate comprising one or more ankyrin repeat, or fragment thereof, in conditions under which the substrate is hydroxylated in the absence of the test agent; and determining hydroxylation of the substrate. | 09-18-2008 |
| 514425000 | Plural chalcogens bonded directly to the five-membered hetero ring by nonionic bonding | 26 |
| 20110201666 | COMPOUNDS FROM MYCELIUM OF ANTRODIA CINNAMOMEA AND USE THEREOF - The present invention relates to compounds from mycelium of | 08-18-2011 |
| 20090069406 | Analogs of tetramic acid - Tetramic acid analogues of Formula I and Formula II have antibacterial activity, primarily against gram-positive bacteria, and are iron chelators. | 03-12-2009 |
| 20100099736 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT - The invention discloses the use of a compound of formula (I), wherein R | 04-22-2010 |
| 20130059900 | CRYSTAL FORM I OF (S)-4-HYDROXY-2-OXO-1-PYRROLIDINE ACETAMIDE, PREPARING METHOD AND USE THEREOF - A crystal form I of (S)-4-hydroxy-2-oxo-1-pyrrolidine acetamide, or named (S)-oxiracetam, is provided, which is characterized by a powder x-ray diffraction pattern that exhibits data of d-values versus the relative intensities as: 7.075(M), 5.355(S), 5.092(S), 4.590(M), 4.325(M), 4.259(S), 4.041(VS), 3.808(M), 3.542(M), 3.445(M), 3.393(M), 2.972(M), 2.914(S). A method for preparing a crystal form I of (S)-oxiracetam is also provided, which includes preparing the crude product and crystallizing A use of the crystal form I of (S)-oxiracetam in the manufacture of a medicament for preventing and treating memory dysfunction is also provided. Accordingly, the crystal form I of (S)-oxiracetam prepared by the method has high purity of more than 99.3% based on the percentages of the mass, with better efficacy than (S)-oxiracetam for preventing or treating memory dysfunction. Concerning the way of charging materials, adding inorganic base only a few times is simpler and more beneficial to industrial manufacturing and application. | 03-07-2013 |
| 20090012152 | Use of Tetramic Acid Derivatives for Controlling Insects from the Genus of the Plane Lice (Sternorrhyncha) - The present invention relates to the use of tetramic acid derivatives of the formula (I) | 01-08-2009 |
| 20110301217 | Selective Glycosidase Inhibitors and Uses Thereof - The application relates to an immoalditol compound for selectively inhibiting glycosidases, a prodrug thereof and a pharmaceutical composition comprising the compound or the prodrug The application also relates to the use of the immoalditol compound for treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc Such diseases and disorders include neurodegenerative diseases, tauopathy, cancers, and cardiac disorders | 12-08-2011 |
| 20100022615 | ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS - Activated cytotoxic compounds are described for attachment to targeting molecules for the treatment of a mammalian disease condition which comprise, an activator, a spacer linker, a linker (e.g., self-immolative), and a cytotoxic drug selected from the group consisting of AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES, AMINO-AND-HYDROXY SUBSTITUTED STYRYLSULFONANILIDES, and SUBSTITUTED PHENOXY- AND PHENYLTHIO-STYRYLSULFONE DERIVATIVES. Activated cytotoxic compound attached to a targeting molecule are described wherein the targeting molecule is selected from the group consisting essentially of an antibody, a receptor, a ligand, a cytokine, a hormone, and a signal transduction molecule. The invention is further directed to a method of treatment of disease conditions. | 01-28-2010 |
| 20090306174 | Novel Five-Membered Iminocyclitol Derivatives as Selective and Potent Glycosidase Inhibitors: New Structures for Antivirals and Osteoarthritis Therapeutics - Novel 5-membered iminocyclitol derivatives were found to be a potent and selective inhibitors of the glycoprotein processing α- and β-glucosidase which were further found to be active antiviral agents against Japanese encephalitis virus, dengue virus serotype 2 (DEN-2), human SARS coronavirus and human β-hexosaminidase, a new target for development of osteoarthritis therapeutics. | 12-10-2009 |
| 20080280972 | Iminosugar treatment of tumors - A proliferation of cells can be reduced by contacting the cells with a compound having formula (I) | 11-13-2008 |
| 20080269317 | Compounds for Covalent Binding to MD-2 and Effect on the Immune Response - Compounds having a hydrophobic group with a group and capable of reacting with the cysteine residue for the binding to protein MD-2 are disclosed. The compounds are capable of covalently binding to MD-2, which can be either free or in the complex with other molecules. The compounds are capable of replacing other ligands or preventing a binding of other ligands, especially bacterial endotoxin (lipopolysaccharide-LPS), which can otherwise lead towards unwanted activation of the immune response and acute or chronic inflammatory diseases. | 10-30-2008 |
| 20100160409 | Highly Branched Reagents For Modifying Biopharmaceuticals, Their Preparation And Use - The invention relates to compounds, which are suitable for coupling to pharmaceuticals, in particular biopharmaceuticals, in addition to conjugates from the compounds comprising biomolecules or pharmaceutically active substances. The inventive compounds are highly cross-linked and can be formed in a simple manner by using a central cross-linking module. The invention also relates to the use of conjugates as an improved formulation of pharmaceuticals and to the production thereof. | 06-24-2010 |
| 20090048330 | Compound from Antrodia camphorata and the use thereof - The present invention relates to novel compounds from | 02-19-2009 |
| 20100179211 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION - The present invention relates to the use of compounds which increase extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically to the use of 3-disubstituted phenyl-1-pyrrolidinols for the treatment of central nervous system disorders. | 07-15-2010 |
| 20110098336 | PYRROLIDIN-2-ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR - A compound represented by the formula (I) according to claim | 04-28-2011 |
| 20110077282 | NOVEL COMPOUNDS FROM ANTRODIA CAMPHORATA - Disclosed herein are isolated compounds or pharmaceutically acceptable salts thereof, which exhibit immunostimulatory or anti-inflammatory effects. The compounds are isolated from the fruiting body of | 03-31-2011 |
| 20110257242 | 3-PHENYL-3-METHOXYPYRROLIDINE DERIVATIVES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION - The present invention relates to novel 3-phenyl-3-methoxy-pyrrolidine derivatives, useful for modulating dopamine neurotransmission and extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders. In other aspects the invention relates to pharmaceutical compositions comprising the 3-phenyl-3-methoxy-pyrrolidine derivatives of the invention and to the use of these compounds for therapeutic applications. | 10-20-2011 |
| 20080207734 | Novel alkoxylactones, alkoxylactams and alkoxythiolactams for controlling processes based on microbial interaction - Compounds of the Formula I, | 08-28-2008 |
| 20090176861 | Cathepsin cysteine protease inhibitors - The present invention relates to a novel class of compounds mainly, substituted leucinamide-carboxylate derivatives of formula (I) wherein X is O or NR | 07-09-2009 |
| 20120046337 | Novel Five-Membered Iminocyclitol Derivatives as Selective and Potent Glycosidase Inhibitors: New Structures for Antivirals and Osteoarthritis Therapeutics - Novel 5-membered iminocyclitol derivatives were found to be a potent and selective inhibitors of the glycoprotein processing α- and β-glucosidase which were further found to be active antiviral agents against Japanese encephalitis virus, dengue virus serotype 2 (DEN-2), human SARS coronavirus and human β-hexosaminidase, a new target for development of osteoarthritis therapeutics. | 02-23-2012 |
| 20090030065 | Use of Pde1c and Inhibitors Thereof - The present invention relates to the use of PDE1C as a novel target for the identification of compounds, which can be used for the treatment of pulmonary hypertension, fibrotic lung diseases or other fibrotic diseases outside the lung. The present invention further relates to the use of PDE1C inhibitors in the manufacture of pharmaceutical compositions for use in the therapy of those diseases. | 01-29-2009 |
| 20100152277 | DIACYLGLYCEROL ACYLTRANSFERASE ASSAY - The present invention generally provides a method of measuring the biological activity of diacylglycerol acyltransferase (DGAT). Specifically, the present invention provides a method for rapid, mass screening of compounds which are able to modulate the biological activity of DGAT. More specifically, the present invention provides an assay system for measuring DGAT activity based on the use of particular micelles with the FlashPlate™ technology. | 06-17-2010 |
| 20120016001 | SUCCINIMIDE DERIVATIVES AS OCULAR HYPOTENSIVE AGENTS - The present invention provides methods and pharmaceutical compositions for treating ocular disorders associated with elevated intraocular pressure, such as glaucoma, by administering antiepileptic or anti-convulsant compounds of the succinimide family, in particular compounds of formula I and/or II as defined herein. | 01-19-2012 |
| 20090069405 | TREATMENT OF CNS AND PAIN DISORDERS - A method of treating a patient suffering from a condition or disorder selected from chronic pain, neuropathic pain, fibromyalgia, migraine, bipolar disorder and depression comprises the administration of a pharmacologically effective amount of 3-(phenylmethylamino-methylene)pyrrolidine-2,4-dione (I) or a pharmaceutically acceptable salt or prodrug or solvate thereof. Also disclosed is the use of (I) for the manufacture of a pharmaceutical composition for treatment of such condition or disorder. | 03-12-2009 |
| 20120258997 | NEW APPLICATION OF 2-PYRROLIDONE DERIVATIVES - The invention is related to the new application of selected derivatives of 2-pyrrolidone to inhibition of protein glycation and to prevention and treatment of diabetes complications, such as atherosclerosis, nephropathy, retinopathy, cataract or neuropathy. | 10-11-2012 |
| 20100130584 | NOVEL COMPOUNDS FROM ANTRODIA CAMPHORATA - Compounds isolated from the fruiting body of | 05-27-2010 |
| 20120149753 | USE OF NOVEL COMPOUNDS FROM FRUITING BODY OF ANTRODIA CAMPHORATA FOR TREATING AN INFLAMMATORY DISORDER - Disclosed herein are isolated compounds or pharmaceutically acceptable salts thereof, which exhibit immunostimulatory or anti-inflammatory effects. The compounds are isolated from the fruiting body of | 06-14-2012 |
